Followers | 751 |
Posts | 16573 |
Boards Moderated | 1 |
Alias Born | 05/30/2007 |
Saturday, October 12, 2019 12:12:44 AM
By S. Jack Heffernan Ph.D on August 19, 2018
We have continued to move along the path to the name change, restructure and launch.
Interest in our blockchain services has continued to increase even though cryptocurrencies have taken a hit of late. The future application of blockchain technology will become a ubiquitous part of everyday life and HEFFX has one of the most robust and responsive platforms in the market.
Trading will be making a big splash for HEFFX in 2018, our new platform will offer over 50,000 securities including over 10,000 stocks from around the globe — all from one single account. Blue chips or new IPOs, great US markets or local European exchanges — select your preference and create your perfect portfolio. We also offer access to a unique range of ETFs for all purposes, whether you prefer high volatility or are looking for conservative safe investment opportunities, our crypto funds allow for a one-click purchase of bitcoin and 15 most popular altcoins including Ethereum, Litecoin, Monero and Ripple.
The combination of cash investments and services for equity has also added significant growth, one of our biotech investments is soon to launch in Asia and we have a diverse portfolio of assets from fashion to mining.
Regular readers of our News Service would have seen a marked increase in content over the past few months with the site now providing coverage of global trade ideas, politics, horse racing, Ferrari and travel.
Although the process has been painfully slow HEFFX will hit the market with one single feature that not many companies on the OTC can claim, 100% debt free, no convertible toxic debt limiting our upside. As the company moves towards a NASDAQ listing there will be a leadership succession plan in place to appoint a new CEO and board most likely in Singapore.
We are looking forward to an exciting end to 2018.
https://www.livetradingnews.com/heffx-update-5-102695.html#.XaFR3WZCTFJ
$$$BZTG$$$
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM